Format

Send to

Choose Destination
See comment in PubMed Commons below
J Hum Hypertens. 2011 Apr;25(4):271-7. doi: 10.1038/jhh.2010.45. Epub 2010 May 6.

The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics.

Author information

1
Department of Evidence-Based Medicine, Cardiovascular Institute and Fuwai Hospital, Beijing, PR China.

Abstract

The Chinese Hypertension Intervention Efficacy Study (CHIEF) is a multi-centre randomized controlled clinical trial comparing the effects of amlodipine+angiotensin II receptor blocker and amlodipine+diuretics on the incidence of cardiovascular events, represented as a composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death events in high-risk Chinese hypertensive patients. The study also evaluates the long-term effects of lipid-lowering treatment and lifestyle modification. From October 2007 to October 2008, 13,542 patients were enrolled into the study in 180 centres in China. Patients will be followed up for 4 years. There was no difference in baseline characteristics between the two blood pressure arms.

PMID:
20445570
PMCID:
PMC3061000
DOI:
10.1038/jhh.2010.45
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center